鲍曼不动杆菌的耐药机制及其治疗药物

摘要

鲍曼不动杆菌已成为世界范围内导致院内感染的重要病原菌之一，环境适应能力及耐药能力强，因此给临床治疗带来了巨大的挑战。随着多种广谱抗生素尤其是碳青霉烯类的大量应用，使其耐药性不断增强，而新型药物的研发速度却远远无法满足临床需求，这种局面迫使对20世纪70年代弃用的粘菌素的再启用。此外，联合疗法似已显现了更高的杀菌活性，但具体的效果还有待进一步的临床试验证实。针对鲍曼不动杆菌的耐药机制以及有关的治疗药物进行综述，从而为防治相关感染以及研发新型药物提供理论基础。%Acinetobacter baumanni has become an important pathogen causing nosocomial infections worldwide.Its powerful environmental adaptability and drug resistance have brought great challenges to clinical treatment.Drug resistance increased rapidly with the use of multiple broad-spectrum antibiotics, especially the use of carbapenem and the development of new drugs is far from meeting clinical needs.This situation resulted in the reuse of colistin which has been used in 1970s.On the other hand, the combination therapy showed higher bactericidal activities, but the specific effect remains to be con-firmed by further clinical trials.In this review, we summarized the drug resistance mechanism of Acinetobacter baumannii and related drugs, thus to provide a theoretical basis for the prevention and treatment of Acinetobacter baumannii infection.